Head and Neck Squamous Cell Carcinoma Clinical Trials

67 studies are recruiting for head and neck squamous cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

   This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Providence Medical Foundation (site 209), Santa Rosa, California

   Locations

   13 in total

   Run by

   VM Oncology, LLC

   See if you can join NCT03556228 on ClinicalTrials.gov

2. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

   This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama, Birmingham, Alabama

   Locations

   12 in total

   Run by

   Compass Therapeutics

   See if you can join NCT06150664 on ClinicalTrials.gov

3. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   40 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

4. PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer

   This early phase I trial compares sodium fluoride F-18 (F-18 NaF) positron emission tomography (PET)/computed tomography (CT) to the standard of care imaging scan (and fludeoxyglucose F-18 [F-18 FDG] PET/CT) for assessing the effects radiation therapy has on the blood vessels in the neck in patient…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Emory University Hospital Midtown, Atlanta, Georgia

   Run by

   Emory University

   See if you can join NCT06914999 on ClinicalTrials.gov

5. High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

   This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation tre…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona

   Locations

   216 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT06992427 on ClinicalTrials.gov

6. Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

   Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if they spread to othe…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07667400 on ClinicalTrials.gov

7. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSD, La Jolla, California

   Locations

   54 in total

   Run by

   Genmab

   See if you can join NCT03526835 on ClinicalTrials.gov

8. A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in combination with pembrolizumab in adult patients with selected squamous s…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Foundation for Medical Education and Research - Mayo Cl, Scottsdale, Arizona

   Locations

   41 in total

   Run by

   Alentis Therapeutics AG

   See if you can join NCT06747585 on ClinicalTrials.gov

9. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   25 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

10. A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases. This study aims to evaluate the change in disease activity and optimal dose, and optimal dose of telisotuzumab adizutecan in combination with pembrolizu…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City Of Hope Comprehensive Cancer Center /ID# 281939, Duarte, California

    Locations

    5 in total

    Run by

    AbbVie

    See if you can join NCT07744126 on ClinicalTrials.gov

11. Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

    This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

    Locations

    12 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06980038 on ClinicalTrials.gov

12. PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

    The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06239220 on ClinicalTrials.gov

13. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest /ID# 283487, Grand Rapids, Michigan

    Locations

    3 in total

    Run by

    AbbVie

    See if you can join NCT07807956 on ClinicalTrials.gov

14. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center /ID# 258645, Duarte, California

    Locations

    54 in total

    Run by

    AbbVie

    See if you can join NCT06084481 on ClinicalTrials.gov

15. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

    A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 105 - START Los Angeles, Los Angeles, California

    Locations

    8 in total

    Run by

    EpiBiologics

    See if you can join NCT07462377 on ClinicalTrials.gov

16. Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell Carcinoma

    This observational study will examine how closely first-window indocyanine green (ICG) fluorescence corresponds to the extent of head and neck squamous cell carcinoma identified by tissue biopsy. ICG is a fluorescent dye given into a vein during surgery. Patients receive ICG as part of their clinic…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07825597 on ClinicalTrials.gov

17. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Grand Rapids, Michigan

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07115043 on ClinicalTrials.gov

18. CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

    This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07659678 on ClinicalTrials.gov

19. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moores Cancer Center UC San Diego Health, La Jolla, California

    Locations

    21 in total

    Run by

    Bicara Therapeutics

    See if you can join NCT04429542 on ClinicalTrials.gov

20. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Gilbert, Arizona

    Locations

    20 in total

    Run by

    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

21. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Precision NextGen Oncology, Beverly Hills, California

    Locations

    8 in total

    Run by

    Neonc Technologies, Inc.

    See if you can join NCT06047379 on ClinicalTrials.gov

22. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

23. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

    This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chem…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Anchorage Associates in Radiation Medicine, Anchorage, Alaska

    Locations

    679 in total

    Run by

    ECOG-ACRIN Cancer Research Group

    See if you can join NCT02734537 on ClinicalTrials.gov

24. A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

    The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

    Stage

    Not phased

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    32 in total

    Run by

    Tempus AI

    See if you can join NCT06163534 on ClinicalTrials.gov

25. A Study of IDP-001 in Advanced or Metastatic Solid Tumors

    This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Los Angeles, Los Angeles, California

    Locations

    6 in total

    Run by

    InduPro, Inc.

    See if you can join NCT07602842 on ClinicalTrials.gov